CSL Behring

CSL Behring is a global biotechnology leader specializing in the development and manufacturing of biotherapies for rare and serious diseases. As a subsidiary of CSL Limited, the company has been dedicated to saving and improving lives for over a century.

Their extensive portfolio includes plasma-derived and recombinant therapies that address a wide range of medical conditions.

The company's product offerings encompass treatments for bleeding disorders, immune deficiencies, hereditary angioedema, neurological disorders, and Alpha-1 Antitrypsin Deficiency.

These therapies are designed to meet the unmet medical needs of patients worldwide, reflecting CSL Behring's commitment to innovation and patient-centric care.

In addition to its therapeutic products, CSL Behring operates one of the largest and most efficient plasma collection networks globally. This network is crucial for sourcing the high-quality plasma needed to produce their therapies.

The company's dedication to safety, quality, and customer service is evident in its comprehensive research and development efforts, as well as the support services it provides to those who rely on its products.

CSL Behring's core values—Patient Focus, Innovation, Integrity, Collaboration, and Superior Performance—underscore its commitment to delivering the best possible therapies and services.

These principles guide the company's operations and interactions with patients, healthcare providers, and partners.

Locations

• King of Prussia, Pennsylvania, USA
• Broadmeadows, Victoria, Australia
• Marburg, Germany
• Bern, Switzerland
• Collingswood, NJ, USA
• New Orleans, LA, USA
• Bloomington, IN, USA
• Orlando, FL, USA
• Boise, ID, USA
• Gresham, OR, USA
• Las Vegas, NV, USA

These sites are integral to the company's research, development, and manufacturing operations, ensuring the delivery of life-saving therapies to patients around the world.

In summary, CSL Behring stands at the forefront of biotechnology, driven by a promise to save and improve lives through innovative therapies and a steadfast commitment to patient care.